Sierra Oncology, Inc. announced the appointment of Dr. Stephen Dilly as President, effective June 1, 2020. In addition, Dr. Dilly and Mr. Craig Collard have been appointed to the company's Board of Directors. Dr. Stephen Dilly brings three decades of executive management experience in the biopharmaceutical industry. Most recently, Dr. Dilly served as CEO and Board Member of Aimmune Therapeutics. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development and launch of several marketed drugs. Dr. Dilly also currently serves on the Board of Directors of one public biotechnology company and several private companies. Mr. Craig Collard is currently the CEO of Veloxis Pharmaceutics, Inc., now a subsidiary of Asahi Kasei after its acquisition of Veloxis for $1.3 billion in 2020. Prior to this, he served as the CEO and Chairman of Cornerstone Therapeutics, Inc. until February 2014 when the company was purchased by Chiesi Pharmaceuticals, Inc. Before founding Cornerstone, Mr. Collard served as President and CEO of Carolina Pharmaceuticals, Inc. Mr. Collard is a member of the Board of Directors of Veloxis, Opiant Pharmaceutics, Inc. and TerrAscend Corporation.